{"url_path":"/sec/sbfm/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-005656-index.html","accession_number":"0001683168-26-005656","cik":"0001402328","ticker":"SBFM","issuer_name":"Sunshine Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-005656-index.html","primary_entity_key":"0001402328","primary_entity_name":"Sunshine Biopharma Inc."},"word_count":103,"has_tables":true,"body_markdown":"****\n\n \n\n**Item\n9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n5.1\n \n[Opinion of Hart & Hart, LLC](sunshine_ex0501.htm)\n\n10.1\n \n[At-The-Market Issuance Sales Agreement, dated July 20, 2026](sunshine_ex1001.htm)\n\n23.1\n \nConsent of Hart & Hart, LLC (included in [Exhibit 5.1](sunshine_ex0501.htm))\n\n104\n \nCover Page Interactive Data File (formatted in Inline XBRL).\n\n \n\n \n\n \n\n \n\n** **\n\n****\n\n 2 \n\n \n\n**** \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDated: July 20, 2026\n**SUNSHINE BIOPHARMA INC.**\n\n \n \n\n \n \n\n \nBy: /s/ Dr. Steve N. Slilaty                                           \n\n \n\nName: Dr. Steve N. Slilaty\nTitle: Chief Executive Officer\n\n \n\n** **\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 3"}